Anthony Behin

Anthony Behin

Auto-generated profile, based on publicly available information

Anthony Behin

Institut de Myologie, Centre de Référence de Pathologie Neuromusculaire Paris-Est, GH Pitié-Salpêtrière, Paris, France

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in The Lancet
Verified
Journal Article
Closed access
ABAnthony Behin
Anthony Behin
KHKhe Hoang-Xuan
Khe Hoang-Xuan
ACAntoine F Carpentier
Antoine F Carpentier
JDJean-Yves Delattre
Jean-Yves Delattre

1 May 2014 in Medicine
Verified
Journal Article
Open access
YAYves Allenbach
Yves Allenbach
LDLaurent Msc Drouot
Laurent Msc Drouot
ARAude Rigolet
Aude Rigolet
JCJean Luc Charuel
Jean Luc Charuel
FJFabienne Jouen
Fabienne Jouen
OBOlivier MD Benveniste
Olivier MD Benveniste
Necrotizing autoimmune myopathy (NAM) is a group of acquired myopathies characterized by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers identified autoantibodies (aAb) against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in patients with NAM, especially in statin-exposed patients. Here we report what is to our knowledge the first European cohort of patients with NAM. The serum of 206 patients with suspicion of NAM was tested for detection of anti-HMGCR aAb using an addressable laser bead immunoassay. Forty-five patients were found to be anti-HMGCR positive. Their mean age was 48.9 ± 21.9 years and the group was predominantly female (73.3%). Statin exposure was recorded in 44.4% of patients. Almost all patients had a muscular deficit (97.7%), frequently severe (Medical Research Council [MRC] 5 ≤3 in 75.5%). Subacute onset (<6 mo) was noted for most of them (64.4%). Nevertheless, 3 patients (6.6%) had a slowly progressive course over more than 10 years. Except for weight loss (20%), no extramuscular sign was observed. The mean CK level was high (6941 ± 8802 IU/L) and correlated with muscle strength evaluated by manual muscle testing (r = −0.37, p = 0.03). Similarly, anti-HMGCR aAb titers were correlated with muscular strength (r = −0.31; p = 0.03) and CK level (r = 0.45; p = 0.01). Mean duration of treatment was 34.1 ± 40.8 months, and by the end of the study no patient had been able to stop treatment. This study confirms the observation and description of anti-HMGCR aAb associated with NAM. The majority of patients were statin naive and needed prolonged treatments. Some patients had a dystrophic-like presentation. Anti-HMGR aAb titers correlated with CK levels and muscle strength, suggesting their pathogenic role.

17 April 2016 in Brain
Verified
Journal Article
Open access
PDF file
YAYves Allenbach
Yves Allenbach
JKJeremy Keraen
Jeremy Keraen
ABAnne-Marie Bouvier
Anne-Marie Bouvier
VJValérie Jooste
Valérie Jooste
NCNicolas Champtiaux
Nicolas Champtiaux
OBOlivier Benveniste
Olivier Benveniste
Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients.

11 March 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
OBOlivier Benveniste
Olivier Benveniste
LDLaurent Drouot
Laurent Drouot
FJFabienne Jouen
Fabienne Jouen
JCJean-Luc Charuel
Jean-Luc Charuel
CBCoralie Bloch-Queyrat
Coralie Bloch-Queyrat
OBOlivier Boyer
Olivier Boyer
Objective Anti–signal recognition particle (anti‐SRP) autoantibodies are associated with severe acquired necrotizing myopathies. The role of these autoantibodies remains elusive, and the evolution of anti‐SRP levels over time is unknown. In this study, we developed an addressable laser bead immunoassay (ALBIA) technique to investigate a correlation between anti‐SRP levels, serum creatine kinase (CK) levels, and muscle strength in patients with necrotizing myopathy. Methods The diagnostic value of the ALBIA assay was determined by comparing serum levels of anti‐SRP autoantibodies in 31 anti‐SRP immunodot–positive patients to those in 190 healthy blood donors and 199 control patients with different inflammatory/autoimmune conditions or polyclonal hypergammaglobulinemia. Among the 31 anti‐SRP–positive patients, serum samples from 8 patients were monitored over time for levels of anti‐SRP autoantibodies and levels of CK (determined at least 3 times, consecutively, over a mean followup period of 783 days). The relationship between levels of anti‐SRP autoantibodies and levels of CK was tested using a linear mixed model. Results The assay yielded positive results for anti‐SRP in all anti‐SRP immunodot–positive serum samples tested, while all control sera tested negative. The 8 anti‐SRP–positive patients who were followed up longitudinally were found to have normalized CK levels and improved muscle strength. There was a striking correlation between the degree of myolysis, as measured by CK levels, in patients receiving therapy and the anti‐SRP54 autoantibody levels in these same patients (P = 0.002). Conclusion Anti‐SRP–positive myositis appears to be one of the few autoimmune diseases in which specific autoantibody levels are correlated with surrogate disease activity markers. These results reveal the usefulness of monitoring anti‐SRP autoantibody levels in patients receiving therapy, and may also suggest a possible pathogenic role for anti‐SRP autoantibodies in the necrotizing myopathies.

1 January 2006 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ACAlexandre Carpentier
Alexandre Carpentier
FLFlorence Laigle-Donadey
Florence Laigle-Donadey
SZSarah Zohar
Sarah Zohar
LCLaurent Capelle
Laurent Capelle
ABAnthony Behin
Anthony Behin
ACAntoine F. Carpentier
Antoine F. Carpentier
Oligodeoxynucleotides containing CpG motifs (CpG ODNs) display a strong immunostimulating activity and drive the immune response toward the Th1 (T he

2 August 2004 in Brain
Verified
Journal Article
Open access
PDF file
KVK. Viala
K. Viala
LRL. Renié
L. Renié
TMT. Maisonobe
T. Maisonobe
ABA. Béhin
A. Béhin
JNJ. Neil
J. Neil
PBP. Bouche
P. Bouche
Lewis–Sumner syndrome (LSS) is a dysimmune peripheral nerve disorder, characterized by a predominantly distal, asymmetric weakness mostly affecting the upper limbs with sensory impairment, and by the presence of multifocal persistent conduction blocks. The nosological position of this neuropathy in relation to multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is still debated. We report the clinical, biological and electrophysiological features, the course and the response to treatment in 23 LSS patients. The initial symptoms started in the distal part of an upper limb in 70% of patients. They were sensorimotor in 65% and purely sensory in 35% of patients. A cranial nerve involvement was observed in 26% of patients and a distal limb amyotrophy in 52%. The CSF protein level was normal in 67% of patients and mildly elevated in the remainder. None had serum anti-GM1 antibodies. There were multiple motor conduction blocks (average of 2.87/patient), predominantly located in the forearm, whereas demyelinating features outside the blocked nerves were rare. Abnormal distal sensory potentials were found in 87% of patients. The electrophysiological pattern suggests a very focal motor fibre demyelination sparing the nerve endings, whereas sensory fibre involvement was widespread. The course was chronic progressive in 71% of patients and relapsing–remitting in the others. During the follow-up study (median duration of 4 years), half of the patients progressed with a multifocal pattern and the distribution of the motor deficit remained similar to the initial presentation. The other patients showed a progression to the other limbs, suggesting a more diffuse process. Fifty-four percent of the patients treated with intravenous immunoglobulin showed an improvement, compared with 33% of the patients treated with oral steroids. Overall, 73% of patients had a positive response to immune-mediated therapy. LSS may be distinguished from MMN by the presence of sensory involvement, the absence of serum anti-GM1 antibodies and, in some cases, a positive response to steroids. In some of the patients in our study, LSS evolved into a more diffuse neuropathy sharing similarities with CIDP. Others had a clinical course characterized by a striking multifocal neuropathy, which suggests underlying mechanisms different from CIDP. Overall, whatever the clinical course, LSS responded to immune-mediated treatment in a manner similar to CIDP.